Pitfalls of valuation in biotech

Journal of Commercial Biotechnology

Volumn 12, Issue 3, 2006, Pages 175-181

  Villiger, Ralph ^a   Bogdan, Boris ^a  

^a Avance   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECH COMPANIES; CASH FLOW METHODS; DRUG DEVELOPMENT PROJECTS;

CONTRACTS; INDUSTRIAL MANAGEMENT; MERGERS AND ACQUISITIONS; PROJECT MANAGEMENT;

BIOTECHNOLOGY;

ARTICLE; BIOTECHNOLOGY; DRUG MARKETING; FINANCIAL MANAGEMENT; INVESTMENT; LICENSING; MERGERS AND ACQUISITIONS;

EID: 34447288086     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3040164     Document Type: Article

References (4)

1. DiMasi, J. A. (2001), 'Risks in new drug development: Approval succss rates for investigational drugs', Clin. Pharmacol. Ther., Vol. 69, pp. 297-307.
2. Villiger, R. and Bogdan, B. (2005), 'Getting real about valuing biotech', Nature Biotechnol., Vol. 23(4), pp. 423-428.
3. Geske, R. (1979), 'Valuation of compound options', Journal of Financial Economics 7, pp. 63-81.
4. Villiger, R. and Bogdan, B. (2005), 'Valuing Pharma R&D: The catch-22 of DCF', J. Appl. Corporate Finance, Vol. 17(2), pp. 113-116.